Qingdao Baheal Medical INC. (301015) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qingdao Baheal Medical INC. (301015) has a cash flow conversion efficiency ratio of 0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥230.38 Million ≈ $33.71 Million USD) by net assets (CN¥2.76 Billion ≈ $404.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 301015 equity to assets ratio to measure how much of total assets are equity-financed.
Qingdao Baheal Medical INC. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Qingdao Baheal Medical INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Qingdao Baheal Medical INC. to evaluate the quality of earnings relative to operating cash generation.
Qingdao Baheal Medical INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qingdao Baheal Medical INC. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sparebanken Vest
OL:SVEG
|
0.056x |
|
Minda Corporation Limited
NSE:MINDACORP
|
0.126x |
|
Zydus Wellness Limited
NSE:ZYDUSWELL
|
0.070x |
|
Opple Lighting Co Ltd
SHG:603515
|
1.058x |
|
Austevoll Seafood ASA
OL:AUSS
|
0.052x |
|
MCC Meili Paper Industry Co Ltd
SHE:000815
|
0.059x |
|
Longshine Technology Co Ltd
SHE:300682
|
0.021x |
|
China Railway Group Limited
F:CNO
|
0.015x |
Annual Cash Flow Conversion Efficiency for Qingdao Baheal Medical INC. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Qingdao Baheal Medical INC. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Qingdao Baheal Medical INC. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.74 Billion ≈ $401.22 Million |
CN¥934.45 Million ≈ $136.74 Million |
0.341x | +9.07% |
| 2024-12-31 | CN¥2.60 Billion ≈ $381.15 Million |
CN¥813.85 Million ≈ $119.09 Million |
0.312x | +21.91% |
| 2023-12-31 | CN¥3.12 Billion ≈ $456.47 Million |
CN¥799.50 Million ≈ $116.99 Million |
0.256x | +91.06% |
| 2022-12-31 | CN¥2.28 Billion ≈ $333.53 Million |
CN¥305.75 Million ≈ $44.74 Million |
0.134x | +60.87% |
| 2021-12-31 | CN¥2.17 Billion ≈ $318.14 Million |
CN¥181.30 Million ≈ $26.53 Million |
0.083x | +206.97% |
| 2020-12-31 | CN¥1.50 Billion ≈ $219.31 Million |
CN¥-116.83 Million ≈ $-17.10 Million |
-0.078x | -321.43% |
| 2019-12-31 | CN¥1.31 Billion ≈ $191.03 Million |
CN¥45.96 Million ≈ $6.73 Million |
0.035x | -31.18% |
| 2018-12-31 | CN¥1.08 Billion ≈ $158.76 Million |
CN¥55.50 Million ≈ $8.12 Million |
0.051x | -- |
About Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more